UK Awaits MHRA Medical Device Fee Consultation While Regulatory Costs Mount
This article was originally published in SRA
Executive Summary
The UK Medicines and Healthcare Products Regulatory Agency's widely anticipated consultation on medical device fees is being delayed as official processes of scrutiny are still being finalized1,2. However, MHRA director of devices John Wilkinson was upbeat last week at the annual regulatory conference of the Association of British Healthcare Industries, saying: “We hope the consultation will be out next month, and when released it will be a proper exercise of six weeks or so.”
You may also be interested in...
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.
Swiss-EU Standoff Set To End? Medtechs Eye MRA Action
Negotiations aimed at renewing the close trading relationship and barrier-free mutual market access between Switzerland and the EU got underway on 19 March. Swiss medtech companies welcomed the move, stressing the need for the defunct mutual recognition agreement to be updated.
A Healthtech Global Software Business With A Silicon Valley Look
Royal Philips’ head of Enterprise Informatics Shez Partovi explains the rationale behind the 2023 decision to set up a vertical business for digital, AI and software applications, to operate alongside imaging, monitoring and interventional therapy.